Infections and prevention of infections in patients with multiple sclerosis;Infektionen und Infektions-prävention bei Multipler Sklerose: Fragen und Antworten für die klinische Praxis

Nervenheilkunde

Volumn 33, Issue 12, 2014, Pages 883-890

  Winkelmann, A ^a   Lobermann M ^a   Reisinger, E C ^a   Zettl, U K ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Disease modifying treatment; Infections; Multiple sclerosis; Vaccinations

Indexed keywords

VACCINE;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; INFECTION PREVENTION; MULTIPLE SCLEROSIS;

EID: 84912073580     PISSN: 07221541     EISSN: 25675788     Source Type: Journal    
DOI: 10.1055/s-0038-1627755     Document Type: Article

References (99)

1. Mix E et al. Animal models of multiple sclerosis - potentials and limitations. Prog Neurobiol 2010; 92(3): 386-404.
2. Baranzini SE et al. Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 2010; 464(7293): 1351-6.
3. Dyment DA et al. Multiple sclerosis In stepsiblings: recurrence risk and ascertainment. J Neurol Neuro surg Psychiatry 2006; 77(2): 258-9.
4. Sawcer S et al. Genetic risk and a primary role for cell-mediated immune mechanisms In multiple sclerosis. Nature 2011; 476(7359): 214-9.
5. Oksenberg JR et al. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008; 9(7): 516-26.
6. Wingerchuk DM. Environmental factors In multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking. Mt Sinai J Med 2011; 78(2): 221-30.
7. Kakalacheva K, Lunemann J. Environmental triggers of multiple sclerosis. FEBS Lett 2011.
8. Ascherio A et al. Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9(6): 599-612.
9. Gardener H et al. Prenatal and perinatal factors and risk of multiple sclerosis. Epidemiology 2009; 20(4): 611-8.
10. Banwell B et al. Clinical, environmental, and genetic determinants of multiple sclerosis In children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011; 10(5): 436-45.
11. Winkelmann A et al. Multiple Sklerose und Infektionskrankheiten. Akt Neurol 2011; 38(07): 339-50.
12. Kamm C, Zettl U. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 2012; 11(3): 196-202.
13. Zettl UK, Stuve O, Patejdl R. Immune-mediated CNS diseases: a review on nosological classification and clinical features. Autoimmun Rev 2012; 11(3): 167-73.
14. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4(3): 195-202.
15. Fernandez AM et al. Microbes, immunity and multiple sclerosis. Curr Immunol Rev 2011; 7(1): 75-82.
16. Stohlman SA, Hinton DR. Viral Induced demyeli-nation. Brain Pathol 2001; 11(1): 92-106.
17. Ruprecht K. Multiple Sklerose und Epstein-Barr Virus: neue Entwicklungen und Perspektiven. Nervenarzt 2008; 79(4): 399-407.
18. Ascherio A, Munch A. Epstein-Barr virus and multiple sclerosis. Epidemiology 2000; 11(2): 220-4.
19. Levin LI et al. Primary Infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010; 67(6): 824-30.
20. Alvarez-Lafuente R et al. Active human herpesvirus 6 Infection In patients with multiple sclerosis. Arch Neurol 2002; 59(6): 929-33.
21. Enbom M. Human herpesvirus 6 In the pathogen-esis of multiple sclerosis. APMIS 2001; 109(6): 401-11.
22. Altschuler EL. Is JC polyoma virus the cause of ul-cerative colitis and multiple sclerosis? Med Hypotheses 2000; 55(4): 335-6.
23. Dessau RB, Lisby G, Frederiksen LJ. Coronavi-ruses In brain tissue from patients with multiple sclerosis. Acta Neuropathol 2001; 101(6): 601-4.
24. Kriesel JD, Sibley WA. The case for rhinoviruses In the pathogenesis of multiple sclerosis. Mult Scler 2005; 11(1): 1-4.
25. Perron H et al. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response In vitro, by Inducing poly-clonal Vbeta16 T-lymphocyte activation. Virology 2001; 287(2): 321-32.
26. Rieger F et al. New perspectives In multiple sclerosis: retroviral Involvement and glial cell death. Pathol Biol (Paris) 2000; 48(1): 15-24.
27. Rolland A et al. Correlation between disease severity and In vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein In patients with multiple sclerosis. J Neuroimmunol 2005; 160(1-2): 195-203.
28. Bergstrom T. Herpesviruses - a rationale for antiviral treatment In multiple sclerosis. Antiviral Res 1999; 41(1): 1-19.
29. Friedman JE et al. A randomized clinical trial of valacyclovir In multiple sclerosis. Mult Scler 2005; 11(3): 286-95.
30. Ramagopalan SV, Sadovnick AD. Epidemiology of Multiple Sclerosis. Neurologic Clinics 2011; 29(2): 207-17.
31. Ascherio A, Munger KL. Epstein-barr virus Infection and multiple sclerosis: a review. J Neuroim-mune Pharmacol 2010; 5(3): 271-7.
32. Hohlfeld R, Toyka K V. (Multiple sclerosis: updates on pathogenesis and treatment: Report from the 9th MS Symposium held by the German Multiple Sclerosis Society). Nervenarzt 2011; 82(8): 1026-35.
33. ∗1501 on multiple sclerosis risk. Neurology 2010; 74(17): 1365-71.
34. Sriram S et al. Chlamydia pneumoniae Infection of the central nervous system In multiple sclerosis. Ann Neurol 1999; 46(1): 6-14.
35. Contini C et al. Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity In a subset of patients with relapsing-remitting multiple sclerosis. Mult Scler 2004; 10(4): 360-9.
36. Ebringer A et al. Acinetobacter immune responses In multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker. Arch Neurol 2005; 62(1): 33-6.
37. Beutler B. Inferences, questions and possibilities In Toll-like receptor signalling. Nature 2004; 430(6996): 257-63.
38. Unterholzner L, Bowie A. The Interplay between viruses and Innate immune signaling: recent Insights and therapeutic opportunities. Biochem Pharmacol 2008; 75(3): 589-602.
39. Gandhi RA et al. Role of the Innate immune system In the pathogenesis of multiple sclerosis. J Neuroimmunol 2010; 221(1-2): 7-14.
40. Carty M, Bowie AG. Evaluating the role of Tolllike receptors In diseases of the central nervous system. Biochem Pharmacol 2011; 81(7): 825-37.
41. Thaiss CA et al. The Interplay between the Innate immune system and the microbiota. Curr Opin Immunol 2014; 26C: 41-48.
42. Bogdanos DP et al. Infectome: a platform to trace Infectious triggers of autoimmunity. Autoimmun Rev 2013; 12(7): 726-40.
43. Iebba VM et al. Gut microbiota and the immune system: an Intimate partnership In health and disease. Int J Immunopathol Pharmacol 2012; 25(4): 823-33.
44. Berer K et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune de-myelination. Nature 2011; 479(7374): 538-41.
45. Manzel A et al. Role of ŽWestern diet" In Inflammatory autoimmune diseases. Curr Allergy Asthma Rep 2014; 14(1): 404.
46. Zoetendal EG, de Vos WM. Effect of diet on the Intestinal microbiota and its activity. Curr Opin Gastroenterol 2014; 30(2): 189-95.
47. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome In human health and disease. Mayo Clin Proc 2014; 89(1): 107-14.
48. Markle JG et al. Sex differences In the gut micro-biome drive hormone-dependent regulation of autoimmunity. Science 2013; 339(6123): 1084-8.
49. Vaarala O. Human Intestinal microbiota and type 1 diabetes. Curr Diab Rep 2013; 13(5): 601-7.
50. Wallberg M, Cooke A. Immune mechanisms In type 1 diabetes. Trends Immunol 2013; 34(12): 583-91.
51. Proal AD et al. The human microbiome and auto-immunity. Curr Opin Rheumatol 2013; 25(2): 234-40.
52. Queiroz-Junior C et al. Experimental arthritis triggers periodontal disease In mice: Involvement of TNF-alpha and the oral Microbiota. J Immunol 2011; 187(7): 3821-30.
53. Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011; 7(10): 569-78.
54. Patejdl R, Zettl UK. Animal models In neurology: drawbacks and opportunities. Curr Pharm De 2012; 18(29): 4443-52.
55. Ponsonby L et al. Exposure to Infant siblings during early life and risk of multiple sclerosis. JAMA 2005; 293(4): 463-9.
56. Hernan MA et al. Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 2006; 67(2): 212-5.
57. Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol 2011; 258: 1197-206.
58. Ristori G et al. Effects of Bacille Calmette-Guerin after the first demyelinating event In the CNS. Neurology 2014; 82(1): 41-8.
59. Winkelmann A et al. Multiple Sclerosis treatment and Infectious issues: update 2013. Clin Exp Immunol 2014; 175(3): 425-38.
60. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b In the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45(7): 1277-85.
61. Goodin D et al. Survival In MS: a randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012; 78(17): 1315-22.
62. Johnson KP et al. Copolymer 1 reduces relapse rate and improves disability In relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45(7): 1268-76.
63. Johnson KP et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50(3): 701-8.
64. Fensterl V, Sen GC. Interferons and viral Infections. Biofactors 2009; 35(1): 14-20.
65. Riminton DS et al. Managing the risks of immuno-suppression. Curr Opin Neurol 2011; 24(3): 217-23.
66. Biogen. Tysabri (web page). 2014; 02 March 2014; Available from: www.Tysabri.de.
67. Vermersch P et al. Clinical outcomes of natalizu-mab-associated progressive multifocal leukoen-cephalopathy. Neurology 2011; 76(20): 1697-704.
68. Dahlhaus S et al. Disease course and outcome of 15 monocentrically treated natalizumab-associ-ated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013, 84(10): 1068-74.
69. Bloomgren G et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012, 366(20): 1870-80.
70. Sorensen PS et al. Risk stratification for progressive multifocal leukoencephalopathy In patients treated with natalizumab. Mult Scler 2012, 18(2): 143-52.
71. Schwab N et al. L-selectin is a possible biomarker for Individual PML risk In natalizumab-treated MS patients. Neurology 2013, 81(10): 865-71.
72. Freedman MS. Treatment options for patients with multiple sclerosis who have a suboptimal response to Interferon-beta therapy. Eur J Neurol 2014; 21(3): 377-e20.
73. Weber T. Progressive multifocal leukoencephalo-pathy. Neurol Clin 2008; 26(3): 833-54.
74. Cohen JA et al. Oral fingolimod or Intramuscular Interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362(5): 402-15.
75. Winkelmann A et al. Fingolimod treatment for multiple sclerosis patients What do we do with varicella? Ann Neurol 2011; 70(4): 673-4.
76. Uhthoff W. Untersuchungen über die bei der multiplen Herdsklerose vorkonimenden Augenstörungen. Archiv für Psychiatrie und Nervenkrankheiten 1890; 21(2): 305-410.
77. Guthrie TC, Nelson DA. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J Neurol Sci 1995; 129(1): 1-8.
78. Oh J, O'Connor P W. Teriflunomide for the treatment of multiple sclerosis. Semin Neurol 2013; 33(1): 45-55.
79. Wiese MD et al. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol 2013; 9(8): 1025-35.
80. O'Connor PW et al. A Phase II study of the safety and efficacy of teriflunomide In multiple sclerosis with relapses. Neurology 2006; 66(6): 894-900.
81. O'Connor P et al. Randomized trial of oral teriflu-nomide for relapsing multiple sclerosis. N Engl J Med 2011; 365(14): 1293-303.
82. Confavreux C et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13(3): 247-56.
83. Yoo HG et al. Risk factors of severe Infections In patients with rheumatoid arthritis treated with le-flunomide. Mod Rheumatol 2013; 23(4): 709-15.
84. Gold R et al. Placebo-controlled phase 3 study of oral G-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367(12): 1098-107.
85. Fox RJ et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer In multiple sclerosis. N Engl J Med 2012; 367(12): 1087-97.
86. Sweetser MT et al. Manufacturer's response to case reports of PML. N Engl J Med 2013; 368(17): 1659-61.
87. van Oosten BW et al. PML In a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368(17): 1658-9.
88. Kothary N et al. Progressive multifocal leukoen-cephalopathy associated with efalizumab use In psoriasis patients. J Am Acad Dermatol 2011; 65(3): 546-51.
89. Hill-Cawthorne GA et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83(3): 298-304.
90. Klotz L et al. Immune mechanisms of new therapeutic strategies In multiple sclerosis-A focus on alemtuzumab. Clin Immunol 2012; 142(1): 25-30.
91. Cohen JA et al. Alemtuzumab versus Interferon beta 1a as first-line treatment for patients with re-lapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012; 380(9856): 1819-28.
92. Coles AJ et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380(9856): 1829-39.
93. De Keyser J et al. Effects of Influenza vaccination and Influenza illness on exacerbations In multiple sclerosis. J Neurol Sci 1998; 159(1): 51-3.
94. Loebermann M et al. Immunization In the adult immunocompromised host. Autoimmun Rev 2012; 11(3): 212-8.
95. Loebermann M et al. Impfen und Multiple Sklerose. Nervenarzt 2010; 81(2): 181-93.
96. Loebermann M et al. Vaccination against Infection In patients with multiple sclerosis. Nat Rev Neurol 2011; 8(3): 143-51.
97. Correale J et al. The risk of relapses In multiple sclerosis during systemic Infections. Neurology 2006; 67(4): 652-9.
98. Boršo D et al. Impfen bei Immundefekten oder medikamentöser Immunsuppression. Dtsch Med Wochenschr 2013; 138(4): 119-125.
99. De Keyser J. Safety of tetanus vaccination In re-lapsing-remitting multiple sclerosis. Infection 1998; 26(5): 319.